Tübingen/ Würz­burg — Masimo, a manu­fac­tu­rer of non-inva­sive pati­ent moni­to­ring tech­no­lo­gies based in Irvine, Cali­for­nia, has agreed on a stra­te­gic invest­ment with TNI medi­cal AG, a medi­cal tech­no­logy company based in Würz­burg, Germany. Funds advi­sed by SHS Gesell­schaft für Betei­li­gungs­ma­nage­ment have been lead inves­tors in TNI medi­cal since 2010. Since then, the Tübin­gen-based medi­cal tech­no­logy and life science inves­tor has supported the company’s growth strategy.

Pati­ents with lung dise­ase receive a stream of warm, moist air applied directly to the nose without conden­sa­tion using TNI’s novel soft­Flow tech­no­logy. The flow rate of the air as well as the humi­dity can be precis­ely adjus­ted and oxygen can be added if neces­sary. The system, consis­ting of an inte­gra­ted flow gene­ra­tor, breathing circuit and pati­ent inter­face, opera­tes without pneu­ma­tic systems (i.e. without the use of extern­ally supplied compres­sed air) and can be used both in the hospi­tal and at home.

“The inno­va­tive products TNI has deve­lo­ped provide clini­ci­ans with important addi­tio­nal tools to treat the growing number of people affec­ted by lung dise­ase,” said Joe Kiani, foun­der, chair­man and CEO of Masimo. “We are plea­sed to provide TNI with an invest­ment that will enable the company to conti­nue to commer­cia­lize its products in the large and rapidly growing high-flow nasal therapy market.”

“We are proud of our successful part­ner­ship with TNI medi­cal, its manage­ment and employees. With the stra­te­gic invest­ment of Masimo, TNI medi­cal can bene­fit from a new part­ner with high exper­tise in inno­va­tive non-inva­sive moni­to­ring tech­no­lo­gies. We look forward to TNI’s future deve­lo­p­ment,” says Rein­hilde Spat­scheck, mana­ging part­ner at TNI’s lead inves­tor SHS Gesell­schaft für Beteiligungsmanagement.

About SHS Gesell­schaft für Betei­li­gungs­ma­nage­ment mbH
Tübin­gen-based SHS Gesell­schaft für Betei­li­gungs­ma­nage­ment invests in medi­cal tech­no­logy and life science compa­nies with a focus on expan­sion finan­cing, share­hol­der chan­ges and succes­sion situa­tions. In doing so, SHS enters into both mino­rity and majo­rity shareholdings.

As an expe­ri­en­ced indus­try inves­tor, the company, which was foun­ded in 1993, supports the growth of its port­fo­lio compa­nies through a network of colla­bo­ra­ti­ons, for exam­ple in the intro­duc­tion of new products, regu­la­tory issues or entry into addi­tio­nal markets. The German and inter­na­tio­nal inves­tors in SHS funds include profes­sio­nal pension funds, pension funds, stra­te­gic inves­tors, funds of funds, family offices, entre­pre­neurs and the SHS manage­ment team. The equity invest­ment of the AIFM-regis­tered company is up to € 30 million, volu­mes excee­ding this can be imple­men­ted with a network of co-inves­tors. Curr­ently, SHS is inves­t­ing from its fifth fund. The fund has alre­ady recei­ved capi­tal commit­ments of over 130 million euros. www.shs-capital.eu